S. Oakninbendahan et al., EFFECTS OF LONG-TERM ADMINISTRATION OF MELATONIN AND A PUTATIVE ANTAGONIST ON THE AGING RAT, NeuroReport, 6(5), 1995, pp. 785-788
ADULT rats were treated with either melatonin, the putative melatonin
antagonist N-(2,4 dinitrophenyl)-5-methoxytryptamine (ML-23), their co
mbination, or a vehicle for 16 months via the drinking water. The surv
ival rates, serum testosterone and densities of I-125-melatonin bindin
g sites in the medulla-pons and hypothalamus of the animals at the age
of 27-29 months were significantly higher in the melatonin than vehic
le-treated group. Surprisingly, ML-23 without or with melatonin, also
prolonged the lifespan of the aged animals. ML-23 treatment greatly in
creased I-125-melatonin binding in the medulla-pons whereas this incre
ase was prevented by melatonin supplementation. Thus melatonin can att
enuate age-related decrease in survival rates, testosterone and brain
I-125-melatonin binding sites, while chronic blockade by the putative
antagonist also elicits melatonin-mimetic responses, perhaps by effect
ing supersensitivity.